Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(10):1669–1671. doi: 10.1038/bjc.1998.274

Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.

J P Peyrat 1, F Révillion 1, J Bonneterre 1
PMCID: PMC2150068  PMID: 9635846

Abstract

Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease in plasma IGF-1.

Full text

PDF
1669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colletti R. B., Roberts J. D., Devlin J. T., Copeland K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989 Apr 1;49(7):1882–1884. [PubMed] [Google Scholar]
  2. Dunn S. E., Hardman R. A., Kari F. W., Barrett J. C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997 Jul 1;57(13):2687–2693. [PubMed] [Google Scholar]
  3. Friedl A., Jordan V. C., Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer. 1993;29A(10):1368–1372. doi: 10.1016/0959-8049(93)90003-x. [DOI] [PubMed] [Google Scholar]
  4. Geier A., Beery R., Haimsohn M., Karasik A. Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest. 1995;13(5):480–486. doi: 10.3109/07357909509024911. [DOI] [PubMed] [Google Scholar]
  5. Guvakova M. A., Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 1997 Jul 1;57(13):2606–2610. [PubMed] [Google Scholar]
  6. Lee A. V., Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother. 1995;49(9):415–421. doi: 10.1016/0753-3322(96)82678-3. [DOI] [PubMed] [Google Scholar]
  7. Lønning P. E., Hall K., Aakvaag A., Lien E. A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992 Sep 1;52(17):4719–4723. [PubMed] [Google Scholar]
  8. Manni A., Boucher A. E., Demers L. M., Harvey H. A., Lipton A., Simmonds M. A., Bartholomew M. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat. 1989 Dec;14(3):289–298. doi: 10.1007/BF01806300. [DOI] [PubMed] [Google Scholar]
  9. Peyrat J. P., Bonneterre J., Hecquet B., Vennin P., Louchez M. M., Fournier C., Lefebvre J., Demaille A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer. 1993;29A(4):492–497. doi: 10.1016/s0959-8049(05)80137-6. [DOI] [PubMed] [Google Scholar]
  10. Peyrat J. P., Bonneterre J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat. 1992;22(1):59–67. doi: 10.1007/BF01833334. [DOI] [PubMed] [Google Scholar]
  11. Pollak M. N., Polychronakos C., Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 1989 Jul-Aug;9(4):889–891. [PubMed] [Google Scholar]
  12. Pollak M., Costantino J., Polychronakos C., Blauer S. A., Guyda H., Redmond C., Fisher B., Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst. 1990 Nov 7;82(21):1693–1697. doi: 10.1093/jnci/82.21.1693. [DOI] [PubMed] [Google Scholar]
  13. Reed M. J., Christodoulides A., Koistinen R., Seppälä M., Teale J. D., Ghilchik M. W. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer. 1992 Sep 9;52(2):208–212. doi: 10.1002/ijc.2910520209. [DOI] [PubMed] [Google Scholar]
  14. Thissen J. P., Ketelslegers J. M., Underwood L. E. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994 Feb;15(1):80–101. doi: 10.1210/edrv-15-1-80. [DOI] [PubMed] [Google Scholar]
  15. Vennin P., Peyrat J. P., Bonneterre J., Louchez M. M., Harris A. G., Demaille A. Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res. 1989 Jan-Feb;9(1):153–155. [PubMed] [Google Scholar]
  16. Yee D., Paik S., Lebovic G. S., Marcus R. R., Favoni R. E., Cullen K. J., Lippman M. E., Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989 Mar;3(3):509–517. doi: 10.1210/mend-3-3-509. [DOI] [PubMed] [Google Scholar]
  17. Zapf J., Froesch E. R. Pathophysiological and clinical aspects of the insulin-like growth factors. Horm Res. 1986;24(2-3):160–165. doi: 10.1159/000180555. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES